期刊文献+

艾森曼格综合征患者EGFR基因突变检测

The Detection of Epidermal Growth Factor Receptor Mutation in Patients with Eisenmenger Syndrome
原文传递
导出
摘要 目的检测艾森曼格综合征患者EGFR基因突变。方法门诊收集23例艾森曼格综合征患者的血浆标本,该23例患者于2008年08月-2015年05曾于我科住院住院治疗,其中动脉导管未闭患者11例,房间隔缺损患者9例,室间隔缺损患者3例。从血浆提取DNA后,经荧光定量PCR法检测EGFR基因。结果 23例艾森曼格综合征患者中共检出EGFR突变2例,检出率约为8%。其中p.L858R突变1例,p.E19-del突变1例。其余20例EGFR均为野生型。结论艾森曼格综合征患者EGFR存在p.L858R、p.E19-del突变。 Objective To detect the mutation of epidermal growth factor receptor(EGFR) in patients with Eisenmenger syndrome(ES). Methods We collected 23 plasma samples with ES who were hospitalized from August 2008 to may 2015,including 11 patent ductus arteriosus cases,9 atrial septal defect cases and 3 ventricular septal defect cases.Free DNA was isolated from plasma.EGFR gene was detected by fluorescence quantitative PCR. Results Somatic mutations in EGFR gene in plasma were identified from 2 of 23(13%) patients.Among the 2 mutants,1 showed p.L858R mutation and 1 showed p.El9-del mutation. Conclusions p.L858R and p.E19-del gene mutations were found in patients with ES.
出处 《中国分子心脏病学杂志》 CAS 2015年第4期1377-1379,共3页 Molecular Cardiology of China
关键词 艾森曼格综合征 表皮生长因子受体 基因突变 Eisenmenger Syndrome Epidermal Growth Factor Receptor Gene Mutation
  • 相关文献

参考文献12

  • 1Paul Wood. The Eisenmenger Syndrome:ll.Br Med J. 1958,2(5099):755-762.
  • 2Godinas L,Guignabert C,Seferian A,et al.Tyrosine kinase inhibitors In Pulmonary arterial hypertension:a double-edge sword? Semin Respir Crit Care Med. 2013,34(5): 714-724.
  • 3Ghofrani HA,Morrell NW, Hoeper MM. lmatinib in pulmonary arterial hypertension patients with inadequate response to establishcd therapy. Am J Respir Crit Care Med. 2010, 182(9): 1171- 1177.
  • 4Hoeper MM,Barst RJ,Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension:results of the randomized IMPRES study. Circulation, 2013,127(10):1128-1138.
  • 5Merklinger SL,Jones PL,Martinez EC,et al. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation, 2005,112(3):423-431.
  • 6Dahal BK,Cornitescu T,Tretyn A,et al.Role of epidermal growth factor Inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med. 2010,181(2): 158-167.
  • 7Yoshida T, Ishii G,Goto K,et al.Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients withEGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol. 2013,139(10): 1691 - 1700.
  • 8Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med.2004,3 50( 21):2129-2139.
  • 9Wu JY, Shih JY, Chen KY, et al.Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine (Baltimore). 2011,90(3): 159-167.
  • 10Pan YL,Xu Y, Feng S,et aI.SKLBI206,a novel orally available Multikinase inhibitor targeting EGFR activating and T790M Mutants,ErbB2,ErbB4 and VEGFR2,displays potent antitumor activity both in vivo and in vitro. Mol Cancer TheJ; 2012,1 1(4):952.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部